SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 719-722. Prepublished online as a Blood First Edition Paper on March 16, 2009; DOI 10.1182/blood-2009-02-204750. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-02-204750v1 114/3/719    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Magro, L. Articles by Yakoub-Agha, I. PubMed PubMed Citation Articles by Magro, L. Articles by Yakoub-Agha, I. Related Collections Transplantation Free Research Articles Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief report Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Leonardo Magro1,*, Mohamad Mohty2,3,*, Benoit Catteau4, Valérie Coiteux1, Patrice Chevallier2, Louis Terriou1, Jean-Pierre Jouet1,5, and Ibrahim Yakoub-Agha1,5,6 1 Service des Maladies du Sang, Centre Hospitalier Regional Universitaire de Lille, Lille; 2 Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes; 3 Université de Nantes, Inserm, Centre de Recherche en Cancérologie de Nantes-Angers U892, Nantes; 4 Service de Dermatologie and 5 EA2686, Centre Hospitalier Regional Universitaire de Lille, Lille; and 6 Centre d'Investigation Clinique en Cancéralogie, Nantes, France Imatinib is a promising candidate for the treatment of fibrotic diseases. This retrospective study evaluated the use of imatinib for the treatment of refractory sclerotic chronic graft-versus-host disease in 14 patients with different hematologic malignancies. Imatinib was started at a median of 44 months after transplantation (range, 16-119 months after transplantation) and was administered for a median of 5.9 months from time of initiation (range, 2.1-74 months from time of initiation). With a median overall follow-up of 11.6 months from time of initiation (range, 4.1-74 months from time of initiation) of imatinib, 4 patients (29%) had to stop imatinib because of drug intolerance. All other adverse reactions were of mild-to-moderate grade and could be managed symptomatically. Overall, 7 patients responded to imatinib (50%; 95% confidence interval, 24%-76%) with 4 patients improving their Rodman score more than or equal to 90%. In addition, imatinib therapy allowed for a significant reduction of corticosteroid dosage. Despite its limited size, this cohort suggests some beneficial activity of imatinib in sclerotic chronic graft-versus-host disease, warranting further prospective investigations. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Magic bullet, part III? Georgia B. Vogelsang Blood 2009 114: 498-499. [Full Text] [PDF] This article has been cited by other articles: D. A. Jacobsohn, A. L. Gilman, A. Rademaker, B. Browning, M. Grimley, L. Lehmann, E. R. Nemecek, K. Thormann, K. R. Schultz, and G. B. Vogelsang Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study Blood, November 12, 2009; 114(20): 4354 - 4360. [Abstract] [Full Text] [PDF] M. Stadler, R. Ahlborn, H. Kamal, H. Diedrich, S. Buchholz, M. Eder, and A. Ganser Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease Blood, October 22, 2009; 114(17): 3718 - 3719. [Full Text] [PDF] G. B. Vogelsang Magic bullet, part III? Blood, July 16, 2009; 114(3): 498 - 499. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020